Found 851 clinical trials
Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy (INMUNOCELL)
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality for recipients of allogeneic hematopoietic stem cell transplantation(HSCT). Recently, strategies based on
- 0 views
- 27 May, 2022
- 1 location
Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients (BK-CTLs)
with BK virus viremia and BK virus-associated symptoms post-allogeneic hematopoietic stem cell transplantation (HSCT), renal transplantation, and chemotherapy.
- 6 views
- 28 Feb, 2022
- 1 location
Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
auto-HSCT.To test the safety and efficacy of giving targeting CD19 and BCMA T cells in treating high risk multiple myeloma followed with auto-HSCT.
- 37 views
- 27 Feb, 2022
- 1 location
Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies
Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies.
- 0 views
- 27 Aug, 2021
- 33 locations
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
) followed by hematopoietic cell transplantation (HCT).
- 4 views
- 30 Apr, 2022
- 1 location
GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL
rituximab) regimen for autologous hematopoietic stem cell transplantation(ASCT)-eligible patients with refractory/relapsed diffuse large B-cell lymphoma.
- 13 views
- 15 Feb, 2022
- 1 location
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy
- 0 views
- 27 Jan, 2021
- 19 locations
Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE
hematopoietic stem cell transplantation (HSCT) have formed the basis allogeneic treatment of this disease, but the results have been poor (60-75% complete remissions-RC-and probability of long-term survival
- 103 views
- 26 Mar, 2022
- 73 locations
Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD
Acute graft-versus-host disease (aGVHD) is the most common life-threatening complication of allogeneic hematopoietic stem cell transplantation. The recognized first-line treatment for grade 3-4
- 0 views
- 02 Sep, 2021
- 1 location
Azacitidine and Homoharringtonine in JMML
Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. Azacitidine and homoharringtonine
- 0 views
- 25 Jan, 2021
- 1 location